07/15/2013
https://congress.gov...
"This lack of predictability in the timing of DEA scheduling decisions leads to unnecessary uncertainty in the drug development process and needless delays in patients' access to new therapies."
"H.R. 4299, the Improving Regulatory Transparency for New Medical Therapies Act, which Ranking Member Pallone and I introduced."
"I yield back the balance of my time and, at this point, recognize the ranking member, Mr. Pallone, 5 minutes for an opening statement."
"I would like to thank all of our witnesses for being here today, and I look forward to having a constructive discussion on these legislative proposals."